Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
BRM421 Ophthalmic Solution, 0.06%
DRUG
2 trials
Sponsors
BRIM Biotechnology Inc.
Conditions
Dry Eye Disease (DED)
Keratoconjunctivitis Sicca
Limbal Stem Cell Deficiency (LSCD)
Phase 2
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Not yet recruiting
NCT07078955
BRIM Biotechnology Inc.
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Start: 2025-12-31
End: 2027-03-31
Target: 99
Updated: 2025-10-20
Unknown Phase
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
NCT07422389
BRIM Biotechnology Inc.
Limbal Stem Cell Deficiency (LSCD)
Updated: 2026-02-20